In an effort to understand this association, there was an increasing interest in the role of glucose‐lowering medications on the risk of COVID‐19 outcomes, given their pharmacological differences and potential direct effect on shared immunometabolic pathways4: the available evidence would suggest small absolute increased rates of COVID‐19 mortality with some dipeptidyl peptidase 4 inhibitors (DPP‐4i, insulin) and reduced with other medications [metformin (MF), sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i), sulphonylurea].5 The gene discussed is DPP4; the disease is COVID-19.